• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    Cosmetic formulation for topical use with dermal, epidermal and anti-wrinkle regeneration capacity consisting of an extemporaneous formulation that, in addition to hyaluronic acid, collagen, hexapeptide-8, acetyl octapeptide-3 acetyl pentapeptide-18, epidermal growth factor egf and factor of fibroblastic growth bfgf, contains: grape seed oil, caprylic/capric triglyceride, glyceryl polyethylene glycol oleate 25 and dimethicoria; sodium hydroxyethyl acrylate/acryloyldimethyl taurate copolymer; and butylated hydroxytoluene, being the result of the interposition in an aqueous phase of hyaluronic acid, collagen, acetyl hexapeptide-8, acetyl octapeptide-3, acetyl pentapeptide-18 and copolymer of hydroxyethyl acrylate/sodium acryloyldimethyl taurate, of an oil phase of egf and the bfgf grape seed oil, caprylic/capric triglyceride, glyceryl polyethylene glycol oleate 25, dimethicone and butylated hydroxytoluene. (Machine-translation by Google Translate, not legally binding)
    公开号:ES2541177A2
    申请号:ES201430036
    申请日:2014-01-15
    公开日:2015-07-16
    发明作者:Teodoro MAYAYO FALO
    申请人:SANI RED S L；SANI-RED SL；
    IPC主号:
    专利说明:

    Description
    COSMETIC FORMULATION OF TOPICAL USE WITH CAPACITY OF DERMAL, EPIDERMAL AND ANTI-WRINKLE REGENERATION OBJECT OF THE INVENTION
    The invention, as expressed in the present specification, refers to a cosmetic formulation for topical use with the ability to dermal, epidermal and wrinkle regeneration.
    More particularly, the object of the invention focuses on a formulation intended for cosmetic treatment at the topical (dermal) level, which combines a short-term effect, by the action of Hyaluronic Acid and acetyl hexapeptide-8 peptides, ( or acetyl octapeptide-3, acetyl pentapeptide-18 ...), and a longer-term skin regeneration effect of so-called growth factors (EGF and bFGF).
    Among the fundamental components, it comprises hyaluronic acid, collagen, acetyl hexapeptide-8, (or acetyl octapeptide-3, acetyl pentapeptide-18 ...); and growth factors such as epidermal growth factor (EGF) and fibroblast growth factor (bFGF), which have been innovatively obtained and biotechnologically modified when formulated accompanied by components such as grapeseed oil, caprylic triglyceride / capríco , glyceryl polyethylene glycol 25 oleate, dimethicone, sodium hydroxyethyl acrylate / acryloxymethyl taurate copolymer and butylhydroxytoluene, so as to favor excellent formulation absorption and allow for short-term mechanical effect and long-term tissue regeneration biological effect. FIELD OF APPLICATION OF THE INVENTION
    The scope of the present invention is framed within the chemical sector, focusing particularly on the field of industry dedicated to the manufacture of cosmetic products, in particular those aimed at improving and providing benefits for the skin and more specifically, referring to the which incorporate hyaluronic acid and / or epidermal growth factor with anti-wrinkle effect and tissue regeneration at epidermal and dermal levels. BACKGROUND OF THE INVENTION
    The aging process has been, for some years, an aesthetic concern that affects a considerable number of the population in developed countries. This process is a normal and natural phenomenon of the organism, where cell regeneration becomes slower and prolonged over time, causing an alteration in the native structure of the skin with the consequent increase in wrinkles and sagging in it. [Bernis e, 2004].
    The skin is a very bulky organ, composed of three layers: epidermis (outermost layer), dermis (intermediate layer) and hypodermis (or subcutaneous tissue). The skin acts as a selective barrier against external agents such as microorganisms, radiation, etc. In this area the phenomenon of aging of a person is observed more immediately, being an indicator of the biological age of the individual, although it does not always correspond to their chronological age, since, in the skin the alterations that are reflected are reflected. they exist in the organism over the years, through "irreversible changes in their structure and functioning" [Gilchrest, 1989].
    The functions that the skin presents are those of protecting the individual from environmental aggressions, helping to control body temperature (thermoregulatory effect), maintaining the balance of fluids and electrolytes, and also containing the nerve receptors that allow the perception of sensations such as touch, pain and pressure.
    In aging, even when the amount of cell layers does not change in the epidermis, it experiences a loss of thickness [Jenkins, 2002]. Additionally, the number of melanocytes (cells containing pigments) decrease and additionally increase their size, so that aging skin appears thinner, pale and transparent (translucent). In addition, with the passage of time and an advanced age, spots called lentigines (or melanic) appear as a consequence, in large part, of sun exposure.
    changes in connective tissue due to age, cause a reduction in the resistance and elasticity of the skin [Francis and Robert, 1984], known as elastosis, which
    It is especially pronounced in areas exposed to the sun (solar elastosis). This condition produces a leathery and deteriorated appearance on the skin, being common in people with professions that develop for a long time outdoors.
    In relation to the conditions associated with age, with respect to the blood vessels that supply the dermis, they become increasingly fragile, resulting in the presence of bruises, bleeding under the skin (also called senile purpura), hemangiomas capillaries and similar conditions [Jenkins, 2002].
    With respect to the sebaceous glands, they produce less sebum as one gets older. Men experience a minimal decrease, usually after 80 years of age, while women gradually produce less sebum after menopause. This fact makes it more difficult to maintain optimal moisture conditions on the skin, causing dryness and itching in the area. On the other hand, carcinogenic conditions, such as skin papillomas, warts and other spots, are more common in older people.
    The fat layer located in the subcutaneous layer performs a function of thermal insulation and mechanical damping, this layer thins over the years with the consequent loss of its characteristics. This increases the risk of skin injury and reduces the ability to exert its thermoregulatory function. Therefore, due to the decrease in natural isolation, the person could suffer a phenomenon of hypothermia in a cold climate. Additionally, the sweat glands produce less sweat, so it becomes more difficult to dissipate the heat generated by the body and there would be a risk of overheating or suffering from heat stroke.
    One of the most abundant molecules in the human body is collagen, a protein that constitutes 25% of the total amount of protein in the body. It appears largely as an essential component of ligaments, tendons, cartilage and skin [Chung et al., 2001]. Like all proteins, it consists of long chains of amino acids, these chains are wound and linked together causing fibers that provide resistance and flexibility to our tissues [Di Lulla et al., 2002). In humans, the production of collagen is carried out through fibroblasts [Bolognia, 1993]; Collagen production begins to decrease progressively between the ages of 20 and 30,
    at approximately 1.5% per year of elapsed age, reducing considerably towards 45 years of age. Around 60 years, production decreases by more than 35%. This reduction of collagen in the human body is the main cause of premature aging, which manifests itself with the loss of elasticity and smoothness in the skin, hair and nails; increased pain in joints, ligaments, tendons and muscles; increased eye problems; Deficiencies in the cardiovascular and lymphatic system; development of discomfort in teeth and gums; and connective tissue diseases or collagenoes (autoimmune disease directed against collagen fibers). Therefore, the reduction of collagen will produce a decrease in skin elasticity that will cause an increase in skin wrinkles [Branchet et al., 1991].
    The so-called epidermal growth factor (EGF), was the first polypeptide isolated and characterized as a growth factor. EGF stimulates cell proliferation and differentiation by binding to the extracellular domain of the EGF receptor (EGFR). On the skin there are epidermal growth factor receptors, which are present in both the dermis and the epidermis. Binding of the ligand to these receptors causes dimerization of the receptor by activating. Activation involves a series of cascade reactions that transmit the signal inside the cell until it provokes the cellular response, which consists of DNA synthesis.
    Said molecule is capable of stimulating the proliferation of keratinocytes and fibroblasts (they secrete EGF which produces the migration of these cells to the damaged tissue and once they reach the place of action they proliferate, thus contributing to the renewal and epidermal repair); activate the synthesis of collagen, the intercellular matrix and the formation of hyaluronic acid, increasing the elastic consistency of the skin and its hydration, because the passage of the years causes the collagen of the dermis to degrade and the elastic fibers and reticulin are disorganized resulting in an intercellular matrix with altered hyaluronic acid; induce angiogenesis (formation of new vessels) and subsequent vascularization of the area where it is applied; at the metabolic level it acts on the superoxide dismutase, exerting an antioxidant action, since with age it decreases the cellular metabolism and activates the dependent calcium membrane systems, improving the transport system of macromolecules and ions into the cellular interior. These properties favor the appearance of new skin with a considerable thickness, returning its elasticity and firmness, thus reducing the unwanted effects of cellular oxidation and thus leading to the elimination of wrinkles [Tang et al., 1994]. The polypeptide was a revolution in clinical by the proliferation, keratinization, repair and regeneration of epidermal tissues, observing that said protein accelerated the proliferation of the epidermis in any culture of epidermal cells. Currently, EGF can be isolated from natural sources, or produced from recombinant DNA techniques or prepared by chemical synthesis. Although it has not been used massively in cosmetic formulations given its high price and its difficult stabilization. It has recently begun to be used in topical formulations, where very good results related to tissue regeneration, acceleration in the healing of burns, treatment of keloids, acne and stretch marks have been obtained, even improving surgical treatment results, favoring skin graft consolidation, as well as post-peeling application. [Schouest et al., 2012].
    In the case of skin aging, the results are still more surprising, since they regulate the remodeling of the dermis and influence the appearance and texture of the skin. So, due to cell regeneration, the skin improves because there is a greater and faster revascularization of it. In addition, they cause the stimulation and production of glycosaminoglycans, collagen and elastin fibers necessary to replace structures altered by aging. Therefore, an increase in this protein in the skin of people with an age of maturity would help reduce aging, and therefore, reduce wrinkles [Bikowski, 2010].
    There are a large number of studies that demonstrate the efficacy of EGF in pathologies other than those of the dermal type. To cite some examples, in one study, they made use of EGF, fibroblasts and hyaluronic acid, and found that there was an absolute improvement in the large perforations of the tympanic membrane when EGF bound to hyaluronic acid was used [Güneri et al., 2003 ; Chauvin et al., 1999].
    Fibroblastic growth factor (bFGF) is found in all tissues of mesodermal and neuroectodermal origin. Endothelial cells produce large amounts of this factor. It is also associated with the extracellular matrix of subendothelial cells. Many cells express bFGF transiently and store it in the inactive form.
    This factor is released after tissue damage and during inflammatory processes. The expression of bFGF is regulated differentially, depending on the type of cell and age. Receptors for FGF (FGFR) and their isoforms are specifically expressed in tissues. However, a cell can express more than one isoform. Different specificities are observed between the different isoforms, in addition the signaling is different for each isoform. Therefore, cells can cause different responses depending on the amount of different receptor isoforms they express (FGFR1, FGFR2, FGFR3, FGFR4) [Gu et al., 2013].
    BFGF stimulates the growth of fibroblasts, myoblasts, osteoblasts, neuronal cells, endothelial cells, keratinocytes, chondrocytes and other cell types; promotes the maturation and maintenance of cholinergic neurons and acts as a mitogen of chromaffin cells; it influences the proliferation, differentiation and function of astrocytes and oligodendrocytes; promotes or inhibits cell differentiation of various cell types; It is involved in angiogenesis by controlling the proliferation and migration of vascular endothelial cells and plays an important role in tissue regeneration and healing [Seifi et al., 2013].
    EGF and bFGF are macromolecules increasingly used in the pharmaceutical and cosmetic industry. They are recombinant proteins produced by biotechnological methods. However, they have not been used massively due to their high prices and their difficult stabilization in a cosmetic formulation. Currently, there are formulations with EGF and / or bFGF for topical application in semi-solid pharmaceutical forms and sterile forms with good results and it is expected that it will be increasingly used due to its ability to improve skin conditions by exerting an effect of cell regeneration.
    On the other hand, hyaluronic acid is a component of connective tissue, which has the ability to retain a large amount of water around it, thus providing elasticity, lubrication, hydration and volume in the skin. Hence it is widely used in the pharmaceutical and cosmetic industry, for presenting a low frequency of complications and allergic reactions, and mainly as an anti-wrinkle treatment. As the body ages, the production of hyaluronic acid decreases, for this reason and with the intention of preserving the skin, reducing and eliminating wrinkles, it has been used in cosmetics [Andre, 2004]. The major problem of the dermal application of hyaluronic acid comes from its structure and molecular weight, since it makes diffusion difficult through the layers of the skin (only penetrates to the most superficial layers of the skin) [Picotti et al., 2012]. This fact hinders its application in the treatment of wrinkles, since it is in the deepest layers of the skin where the greatest loss of collagen and wrinkle formation occurs. In addition, once absorbed, its effect is temporary depending on the concentration present in the area. As a consequence of this fact, attempts have been made to find methods that facilitate the arrival of hyaluronic acid in the area of origin of wrinkles in order to better exert their action.
    Hyaluronic acid is a natural molecule widely used as a medical device in pre-filled syringes, applying for example in joints (20 mg / 2 mL) [Miltner et al., 2002] and facial areas (5.5 mg / mL -24 mg / mL) [Grimes et al., 2009]. With regard to wrinkle treatment, direct injection is currently applied to the wrinkle. The results become visible immediately and last approximately 6 to 8 months. Therefore, hyaluronic acid exerts a mechanical filling action that is achieved immediately. However, this method has some drawbacks: it is an invasive technique (the injection in the facial area is not pleasant for the patient), it can cause risks due to the appearance of bruises or swelling, undesirable adverse effects such as skin hypersensitivity, itching, disorders of the pigmentation of the face, rashes and it would be necessary to apply the treatment from time to time. Additionally, this application technique requires adequate facilities, qualified and experienced personnel to carry it out. Apart from the treatments through injection, formulations with hyaluronic acid combined with adjuvants that improve or enhance their effect, such as peptides [Leach et al., 2004], are being developed. Additionally, hyaluronic acid has been used to improve skin conditions as a food supplement in solid forms of oral administration [Fujikawa, 2008].
    To improve the absorption of hyaluronic acid through the skin, other less invasive techniques have been used that allow the administration of hyaluronic acid and its subsequent absorption by altering the skin's barrier function reversibly, all without causing a traumatic effect or skin irritation. Within these techniques, electroporation and diathermy have achieved some success [Kingsley and Dover, 2010]. With respect to the first of the techniques, electroporation (or electropermeabilization),
    it consists in the emission of a pulsed electromagnetic wave with a determined, athermal and non-ionizable frequency with the purpose of producing an alteration in the permeability of the cell membrane appearing pores for the entry of substances into its interior [Weaver and Chizmadzhev, 1996]. It is a process that has the peculiarity of being reversible and transitory due to the characteristic of the applied wave: pulsed and not constant.
    The use of topical forms, such as creams and gels to apply hyaluronic acid (concentrations from 0.8-3.5%) in cosmetics [Sang-Hyug Park et al., 2011], generates a skin moisturizing effect, since it allows entry from the molecule to the most superficial layers of the skin, despite the effect achieved, for this type of dosage form, it is slower due to the physicochemical characteristics of hyaluronic acid.
    The possibilities of botulinum toxin were studied for the first time in 1987, in this study it was observed that through the injection of the toxin at the facial level there was an improvement in the reduction of wrinkles of expression of the forehead after treating a patient with blepharospasm (abnormal and involuntary contraction of the eyelids); However, until the emergence of the first publications on the treatment of wrinkles between the eyebrows and the peri-ocular region in the 1990s, the usefulness of botulinum toxin in facial treatments was not demonstrated. However, the adverse effects derived from puncture (pain, erythema and edema) and diffusion of the toxin (ptosis of the eyelids and eyebrows, the asymmetry of the smile, sagging, difficulty speaking and inexpression of the face, are known, among other adverse effects) [Ruiz et al., 2007]. In the process of contraction of the muscles, these contract when they receive neurotransmitters released by vesicles, therefore the botox® molecules compete with the natural protein for a position in the SNARE complex (SNApREceptor). If the SNARE complex is destabilized, the vesicles cannot anchor and release the neurotransmitters efficiently and, therefore, muscle contraction is attenuated, preventing the formation of wrinkles. In this sense, molecules with botoX® effect (acetyl hexapeptide-8, acetyl octapeptide-3 and acetyl pentapeptide-18) can be a real alternative to the infiltration of botulinum toxin, since they are capable of reducing muscle contraction and consequently expression wrinkles.
    However, and as a reference to the current state of the art, despite being known the
    use of hyaluronic acid, collagen, peptides with botoX® effect, EGF and bFGF as cosmetic products for the skin, at least by the applicant, the existence of any other cosmetic formulation for topical use for dermal, epidermal regeneration and with anti-wrinkle effect that has similar technical and constitutive characteristics as presented by the one described here, as claimed. EXPLANATION OF THE INVENTION
    Specifically, what the invention advocates is a formulation intended for dermal cosmetic treatment at the topical level combining several products for dermal, epidermal regeneration, anti-wrinkle effect and botox® effect, which combines a short-term effect, by the action of Hyaluronic acid collagen and acetyl hexapeptide-8 peptides, (or acetyl octapeptide-3, acetyl pentapeptide-18 ...), and a longer-term skin regeneration effect of so-called growth factors (EGF and bFGF ).
    Specifically, the fundamental components comprising the proposed formulation are hyaluronic acid, collagen, acetyl hexapeptide-8, (or acetyl octapeptide-3, acetyl pentapeptide-18 ...); and growth factors such as epidermal growth factor (EGF) and fibroblast growth factor (bFGF), which are innovatively accompanied by components such as grapeseed oil, caprylic / capric triglyceride, glyceryl polyethylene glycol 25, dimethicone oleate , sodium hydroxyethyl acrylate / acryloxymethyl taurate and butylhydroxytoluene copolymer, so as to favor excellent absorption of the formulation and allow obtaining a short-term mechanical effect and a long-term tissue regeneration biological effect.
    With this set of natural and biotechnological products, the developed formulation allows the arrival of hyaluronic acid and collagen to the place of action, entering the middle layers of the skin (dermis), and in this way it is possible to retain a large amount of water in said environment generating hydration, lubrication and elasticity in the application area, in addition to generating a powerful anti-wrinkle effect, which is enhanced by a synergistic action of the short chain peptides type acetyl hexapeptide-8, acetyl octapeptide-3 and acetyl pentapeptide- 18, which have a blocking activity in synaptic transmission similar to that of botulinum toxin, relaxing the expression of certain wrinkles. Similarly, the EGF growth factors (capable of stimulating cell growth, proliferation and cell differentiation, in the long term) and bFGF (which facilitates the proliferation of precursor cells such as chondroblast, collagenoblast and osteoblast, will be achieved, among others, stimulating the formation of fibrous tissue) are introduced into the innermost layers of the skin, getting the proteins to exert their effect properly.
    The formulation is the result of the interposition of two well-defined phases, an aqueous phase and an oil phase. The aqueous phase is composed of hyaluronic acid, collagen, acetyl hexapeptide-8, acetyl octapeptide-3, acetyl pentapeptide-18 and sodium hydroxyethyl acrylate / acryloyl dimethyl taurate copolymer, in a gel state prepared in a sterile pharmaceutical form, preferably as a vial . For its part, the oil phase is based on the inclusion of EGF and bFGF, also prepared in a sterile pharmaceutical form but in this case as a blister, and consists of grapeseed oil, caprylic / capric triglyceride, glyceryl polyethylene glycol oleate 25, dimethicone and butylhydroxytoluene. Before its application, the oil phase is mixed with the aqueous phase, by manual agitation, resulting in an extemporaneous formulation, thus ensuring that the proteins remain stable during the formation of the emulsion obtained after mixing the two phases and until the moment of its application.
    More specifically, in the formulation of the present invention, EGF and bFGF are surrounded by an anhydrous medium consisting of other components that help these proteins achieve the desired regenerative effect; These components are: grape seed oil (major component of the oil phase), caprylic / capric triglyceride, glyceryl polyethylene glycol 25 oleate, dimethicone (these components as a whole have a high emollient power that allow maintaining and restoring the hydrolipidic mantle of the skin, favoring its hydration to achieve adequate elasticity and smoothness of the skin) and butylhydroxytoluene (adjuvant exerts an antioxidant action). It should be mentioned that the entire formulation is conveniently conditioned in a sterile pharmaceutical form (ampoule).
    Once both sterile pharmaceutical forms have been obtained with cosmetic application, the formulation constituted by the oil phase where EGF and bFGF are found, accompanied by grapeseed oil, caprylic / capric triglyceride, glyceryl polyethylene glycol 25, dimethicone and butylhydroxytoluene; is interposed in the formulation
    constituted by the aqueous phase of hyaluronic acid, collagen, acetyl hexapeptide-8, acetyl octapeptide-3, acetyl pentapeptide-18 and copolymer of hydroxyethyl acrylate / acryloyl dimethyl taurate; resulting in an extemporaneous cosmetic formulation capable of exerting a mechanical effect (in a short time) induced by hyaluronic acid and peptides with botox effect; and at the same time make a regenerating biological (long-term) effect promoted by the action of growth factors.
    The effect achieved is very similar to that obtained through other forms of sterile administration with pre-loaded syringe injection system) and electroporation application, but without the need to use such system, with the consequent better acceptance by the receiver of the treatment.
    In addition, given the topical application, the extemporaneous formulation allows the penetration of hyaluronic acid into the intermediate area of the epidermis, achieving a filling effect and giving rise to an immediate anti-wrinkle effect. The three-dimensional platform that forms hyaluronic acid helps EGF, bFGF, and collagen diffuse, reach and stimulate the deepest cell layers of the skin promoting tissue regeneration (not localized), thus achieving an anti-wrinkle effect, turgidity , flexibility, luminosity and smoothness, in the long term. The effect of hyaluronic acid is enhanced by the action of peptides hexapeptide-8, acetyl octapeptide-3 and acetyl pentapeptide-18, thanks to a synergistic action of said molecules to obtain the anti-wrinkle effect.
    The application of the described formulation is simple, economical and acceptable by the person who applies it. With a simple massage in the application area, an adequate extension, penetration and absorption of the product is achieved.
    Additionally, its effect can be used and enhanced by means of techniques based on physical principles such as virtual mesotherapy, radiofrequency, electroporation, etc., without damaging or altering the product, which gives an idea of the versatility of the application. of the product.
    The immediate effect, attributable to the components that accompany proteins, such as peptides and hyaluronic acid is remarkable; and to the components that help achieve this effect: grape seed oil, caprylic / capric triglyceride, glyceryl oleate
    polyethylene glycol 25, dimethicone, sodium hydroxyethyl acrylate / acryloxymethyl taurate and butylhydroxytoluene copolymer, since they favor the excellent absorption of the claimed formulation.
    To the mechanical action of peptides and hyaluronic acid in the short term, and to the biological action of EFG and bFGF in the long term, the long-term effect related to the regeneration of skin cells, which is achieved with the hyaluronic acid that reaches deeper layers and prevents the loss of new collagen synthesis of the skin.
    In synthesis, the proposed cosmetic formulation, in a basic embodiment thereof, simply comprises as fundamental components, at least, hyaluronic acid, a peptide such as hexapeptide-8 or acetyl octapeptide-3 or acetyl pentapeptide-18, and the epidermal growth factor EGF, although, preferably, said fundamental components also include the fibroblast growth factor bFGF due to the synergies offered by its molecules, collagen as a complement to hyaluronic acid, and some or all three peptides with the botoX® hexapeptide-8 effect and / or acetyl octapeptide-3 and / or acetyl pentapeptide18, containing in any case, in addition, the rest of the components described: grape seed oil, caprilic / capric triglyceride, glyceryl polyethylene glycol oleate 25 and dimethicone as anhydrous stabilizer of EGF and bFGF; sodium hydroxyethyl acrylate / acryloxymethyl taurate copolymer as a hyaluronic acid stabilizer; and butylhydroxytoluene as an adjuvant of EGF and bFGF with antioxidant action.
    Describing sufficiently the nature of the present invention, it is not considered necessary to make its explanation more extensive so that any expert in the field understands its scope and the advantages that derive from it, stating that, within its essentiality, it can be taken to the practice in other embodiments that differ in detail from that indicated by way of example, and which will also achieve the protection that is sought as long as its fundamental principle is not modified. BIBLOGRAPHY
    -Andre P. Hyaluronic acid and use as a "rejuvenation" agent in cosmetic dermatology. Seminars in cutaneous medicine and surgery 2004; 23: 218-222. -Bemis C. Aging, aged populations and elderly people. Anthropo 2004; 6:
    1-4. -Bikowski JB. Skin serum with human grow1h factor and cytokines for skin rejuvenation. J. of the American Academy of Dermatology 2010; 62: 1604-1606. -Bolognia JL. Dermatologic and cosmetic concerns of the older woman. Clin. Geriatric Med. 1993; 9: 209-229. -Branchet MC, Boisnic S, Frances C et al. Morphometric analysis of dermal collagen fibers in normal human skin as a function of age. Archivers of Gerontology and Geriatrics 1991; 13 (1): 1-14. -Chauvin K, Bratlon C and Parkius C. Healing large tympanic membrane perforations using hyaluronic acid, basic fibroblast grow1h factor, and epidermal grow1h factor. OtoryngologyHead and Neck Surgery 1999; 121: 43-47. -Chung JH, Seo JY, Choi HR et al. Modulation of skin collagen metabolism in aged and photoaged human skin in vivo. The society for investigative dermatology 2001; 117: 12181224. -Lullo GA, Sweeney SM, K6rkk6 J et al. Mapping the Ligand-binding Sites and Diseaseassociated Mutations on the Most Abundant Protein in the Human, Type I Collagen. J. Biol. Chem. 2002; 277 (6): 4223-4231. -Francis C, Robert L. Elastin and elastic fibers in normal and pathologic skin. Int. J. Dermatol. 1984; 23: 166-179. -Fujikawa S. Functions of Hyaluronic Acid and Effects of Its Oral Administration Foods. Food
    Ingredients J. Jpn. 2008; 213: 2. -Garcia F. Transdermal transmission equipment and heat input to internal tissues by radiofrequency. Patent No. 200702686. Spain 2010. -Gilchrest BA. Skin aging and photoageing, An overview. J. Am. Acad. Dermatol 1989; 21: 510-513. -Grimes PE, Thomas JA, Murphy DK. Safety and effectiveness of hyaluronic acid fillers in skin of color. J. Cosmet. Dermatol 2009, 8 (3): 162-8. -Gu Y, Xue C, Zhu J, Sun H, Ding F, Cao Z, Gu X. Basic Fibroblast Grow1h Factor (bFGF) Facilitates Differentiation of Adult Dorsal Root Ganglia-Derived Neural Stem Cells Toward Schwann Cells by Binding to FGFR-1 Through MAPKlERK Activation. J Mol Neurosci. 201 3 -Güneri EA, Tekin S, Yilmaz O, Ozkara E, Erdag TK, Ikiz Aa, Sarioglu S, Güneri A. The effects of hyaluronic acid, epidermal 9row1h factor, and mitomycin in an experimental model of acute traumatic tympanic membrane perforation. Otol Neurotol 2003; 24 (3): 371-6. -Jenkins G. Molecular mechanisms of skin aging. Mechanisms of ageing and development.
    2002; 123: 801-810. -Kingsley M, Dover J. What's new in cosmetic procedures. G. Ital. Dermatol Venereol 2010; 145 (5): 651-8. -Leach JB, Bivens KA, Collins CN, Schmidt CE. Development of photocrosslinkable hyaluronic acid-polyethylene glycol peptide composite hydrogels for 50ft tissue engineering.
    J. Biomed. Mater. Res. A. 2004; 70 (1): 74-82.
    Miltner O, Schneider U, Siebert CH, Niedhart C, Niethard FU. Efficacy of intraarticular hyaluronic acid in patients with osteoarthritis -a prospective clinical trial. Osteoarthritis Cartilage. 2002; 10 (9): 680-6. -Picotti F, Fabbian M, Gianmi R et al. Hyaluronic acid lipoate: synthesis and physicochemical properties. Carbohydr Polym 2013; 93 (1): 273-8. -Ruiz MA, Ciares B, Morales ME, Cazalla S, Gallardo V. Preparation and stability of cosmetic formulations with an anti-aging peptide. J Cosmet Sci. 2007; 58 (2): 157-71. -Sang-Hyug Park, Hongsik Cho, Eun Seok Gil, Biman B. Mandal, Byoung-Hyun Min, David
    L. Kaplan Silk-Fibrin / Hyaluronic Acid Composite Gels for Nucleus Pulposus Tissue Regeneration. Tiss ue Eng PartA. 2011; 17 (23-24): 2999-3009. -Schouest JM, Lun TK, Moy RL. Improved texture and appearance of barley produced, synthetic, human-like epidermal growth factor (EGF) serum. J. Drugs Dermatol. 2012; 11 (5): 613-620. -Seifi M, Badiee MR, Abdolazimi l, Amdjadi P. Effect of basic fibroblast growth factor on orthodontic tooth movement in rats. Cell J. 2013 Fall; 15 (3): 230-7. -Tang l, lhang l, Zheng and et al. Cell aging of human diploid fibroblasts is associated with changes in responsiveness to epidermal growth factor and changes in HER-2 expression. Mechanisms of Ageing and Development 1994; 73 (1): 57-67. -Weaver JC, Chizmadzhev NOW. Theory of electroporation: A review. Bioelectrochemistry and Bioenergetics 1996; 41: 135-160.
    权利要求:
    Claims (5)
    [1]
    1.-COSMETIC FORMULATION characterized in that it comprises hyaluronic acid, collagen, a peptide hexapeptide-8 or acetyl octapeptide-3 or acetyl pentapeptide-18, epidermal growth factor EGF and fibroblast growth factor bFGF, as well as grape seed oil , caprylic / capric triglyceride, glyceryl polyethylene glycol 25 oleate, dimethicone, sodium hydroxyethyl acrylate / acryloxymethyl taurate copolymer and butylhydroxytoluene.
    [2]
    2.-ELABORATION PROCESS OF A COSMETIC FORMULATION, according to claim 1, characterized by being an extemporaneous formulation consisting of interposition in an aqueous phase, composed of hyaluronic acid, collagen, acetyl hexapeptide-8, acetyl octapeptide-3, acetyl Pentapeptide-18 and sodium hydroxyethyl acrylate / acryloxymethyl taurate copolymer, which includes an EGF and bFGF with grapeseed oil, caprylic / capric triglyceride, glyceryl polyethylene glycol 25, dimethicone and butylhydroxytoluene oleate.
    [3]
    3.-ELABORATION PROCESS OF A COSMETIC FORMULATION, according to claim 2, characterized in that the aqueous phase of hyaluronic acid, collagen, acetyl hexapeptide-8, acetyl octapeptide-3, acetyl pentapeptide-18 and hydroxyethyl acrylate / acryloyl dimethyl taurate copolymer Sodium is a gel prepared in a sterile pharmaceutical form as a vial.
    [4]
    4.-ELABORATION PROCESS OF A COSMETIC FORMULATION, according to claim 2, characterized in that the oily phase of EGF, and bFGF, with grape seed oil, caprylic / capric triglyceride, glycerol oleate polyethylene glycol 25, dimethicone and butylhydroxytoluene, is prepared in a sterile pharmaceutical form as a blister.
    [5]
    5.-USE OF A COSMETIC FORMULATION, according to claim 1, to prepare a topical product intended for dermal, epidermal and wrinkle regeneration.
    16
    类似技术:
    公开号 | 公开日 | 专利标题
    ES2659917T3|2018-03-20|Photodynamic therapy | treatment method for cellulite and cosmetic use
    KR101678621B1|2016-11-22|Composition comprising spicules for skin care
    US20190160103A1|2019-05-30|Platelet-rich plasma composition for tissue repair and regeneration
    Levy et al.2009|Comparison of injection comfort of a new category of cohesive hyaluronic acid filler with preincorporated lidocaine and a hyaluronic acid filler alone
    KR20060019540A|2006-03-03|Topical composition for transdermal administration
    CA2645073A1|2007-09-13|Transdermal drug delivery compositions and topical compositions for application on the skin
    WO2014044808A2|2014-03-27|Fast-penetration cosmetic dermal filler for topical application
    CN105687059A|2016-06-22|Cosmetic composition for relieving senescence, as well as preparation method and application thereof
    ES2754523T3|2020-04-20|Stem cell stimulating compositions
    Herman et al.2013|Skin care during the menopause period: noninvasive procedures of beauty studies
    WO2013050959A1|2013-04-11|Composition for the treatment of skin lesions
    CN105496886B|2019-06-25|Phytosphingosine shin moisturizer
    ES2541177B1|2016-06-06|COSMETIC FORMULATION OF TOPICAL USE WITH CAPACITY OF DERMAL, EPIDERMAL AND ANTI-WRINKLE REGENERATION
    Freire dos Santos et al.2018|Split-face, randomized, placebo-controlled, double-blind study to investigate passive versus active dermal filler administration
    KR101917026B1|2019-01-24|Cosmetic composition for skin wrinkle improvement and prevention
    WO2016054757A1|2016-04-14|Pharmaceutical composition for preventing, treating and curing rosacea, comprising snail slime, camomile and propolis
    Beatini et al.2016|Hyaluronic acid hybrid cooperative complexes and the BAP | technique: the new edge in biorejuvenation
    RU2667130C1|2018-09-14|Chitosan-containing hydrogel and method of cosmetic skin care with it use
    KR20090028275A|2009-03-18|Cosmetic materials for anti-aging and winkle reducing effects having essential oil complex as its principal ingredient, and the manufacturing method thereof
    EP2253304B1|2015-11-11|Nifedipine-based compositions for anti-wrinkle treatments
    Majidian et al.2021|Management of skin thinning and aging: review of therapies for neocollagenesis; hormones and energy devices
    RU2659959C1|2018-07-04|Composition of the preparation for correction of skin defects
    KR20070006626A|2007-01-11|Topical composition for transdermal administration
    TW201642846A|2016-12-16|Carboxymethylcysteine for topical treatment of stretch marks
    Lima et al.2021|Percutaneous Collagen Induction With Microneedling
    同族专利:
    公开号 | 公开日
    ES2541177B1|2016-06-06|
    ES2541177R2|2015-08-19|
    WO2015107237A1|2015-07-23|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    US9265792B2|2005-11-16|2016-02-23|Patricia A. Riley|Integument cell regeneration formulation|
    EP2323844A1|2008-09-10|2011-05-25|Silipos Inc.|Gelatinous elastomer compositions|
    CN102652721A|2011-03-03|2012-09-05|成都宇泽生物基因化妆品有限公司|All-in-one skin-care essence|
    CN102349867B|2011-11-02|2013-06-12|广州舒泰生物技术有限公司|Water-replenishing repairing cosmetic as well as preparation method and application thereof|
    CN103340812A|2013-06-25|2013-10-09|开平市美康泉生物科技有限公司|Clear isolation cream|EP3449901A1|2017-09-04|2019-03-06|Dermofarm, S.A.|Cosmetic or dermocosmetic composition, process for its preparation and use thereof|
    CN108379110B|2018-05-16|2021-03-16|广州莎利曼尔生物科技有限公司|Skin care composition, skin care cream and preparation method thereof|
    法律状态:
    2016-06-06| FG2A| Definitive protection|Ref document number: 2541177 Country of ref document: ES Kind code of ref document: B1 Effective date: 20160606 |
    2021-10-04| FD2A| Announcement of lapse in spain|Effective date: 20211004 |
    优先权:
    申请号 | 申请日 | 专利标题
    ES201430036A|ES2541177B1|2014-01-15|2014-01-15|COSMETIC FORMULATION OF TOPICAL USE WITH CAPACITY OF DERMAL, EPIDERMAL AND ANTI-WRINKLE REGENERATION|ES201430036A| ES2541177B1|2014-01-15|2014-01-15|COSMETIC FORMULATION OF TOPICAL USE WITH CAPACITY OF DERMAL, EPIDERMAL AND ANTI-WRINKLE REGENERATION|
    PCT/ES2015/000003| WO2015107237A1|2014-01-15|2015-01-14|Cosmetic formulation for topical use, having a dermal, epidermal and anti-wrinkle regeneration capacity|
    [返回顶部]